PROCF Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -- compared to Sofgen Pharma SA's net margin of -12425.36%. Sofgen Pharma SA's return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Sofgen Pharma SA has a consensus price target of --, signalling upside risk potential of 9900%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 350.83%. Given that Sofgen Pharma SA has higher upside potential than Perspective Therapeutics, Inc., analysts believe Sofgen Pharma SA is more attractive than Perspective Therapeutics, Inc..

Sofgen Pharma SA has a beta of 61.716, which suggesting that the stock is 6071.584% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Sofgen Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sofgen Pharma SA pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Sofgen Pharma SA quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Sofgen Pharma SA's net income of -- is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Sofgen Pharma SA's price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sofgen Pharma SA is 0.01x versus 185.11x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -- compared to Sofgen Pharma SA's net margin of 12.65%. Sofgen Pharma SA's return on equity of -- beat Electromed, Inc.'s return on equity of 18.89%.

Sofgen Pharma SA has a consensus price target of --, signalling upside risk potential of 9900%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 26.49%. Given that Sofgen Pharma SA has higher upside potential than Electromed, Inc., analysts believe Sofgen Pharma SA is more attractive than Electromed, Inc..

Sofgen Pharma SA has a beta of 61.716, which suggesting that the stock is 6071.584% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Sofgen Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sofgen Pharma SA pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Sofgen Pharma SA quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Sofgen Pharma SA's net income of -- is lower than Electromed, Inc.'s net income of $2.1M. Notably, Sofgen Pharma SA's price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sofgen Pharma SA is 0.01x versus 3.80x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Sofgen Pharma SA's net margin of -862.39%. Sofgen Pharma SA's return on equity of -- beat VolitionRX Ltd.'s return on equity of --.

Sofgen Pharma SA has a consensus price target of --, signalling upside risk potential of 9900%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 816.67%. Given that Sofgen Pharma SA has higher upside potential than VolitionRX Ltd., analysts believe Sofgen Pharma SA is more attractive than VolitionRX Ltd..

Sofgen Pharma SA has a beta of 61.716, which suggesting that the stock is 6071.584% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Sofgen Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sofgen Pharma SA pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Sofgen Pharma SA quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Sofgen Pharma SA's net income of -- is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Sofgen Pharma SA's price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sofgen Pharma SA is 0.01x versus 16.45x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Sofgen Pharma SA's net margin of 3.93%. Sofgen Pharma SA's return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Sofgen Pharma SA has a consensus price target of --, signalling upside risk potential of 9900%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 89.11%. Given that Sofgen Pharma SA has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Sofgen Pharma SA is more attractive than Xtant Medical Holdings, Inc..

Sofgen Pharma SA has a beta of 61.716, which suggesting that the stock is 6071.584% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Sofgen Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sofgen Pharma SA pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Sofgen Pharma SA quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Sofgen Pharma SA's net income of -- is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Sofgen Pharma SA's price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 77.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sofgen Pharma SA is 0.01x versus 0.87x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.